Immune Pharmaceuticals Appoints Liquidity Provider to Facilitate Trading on NASDAQ OMX Stockholm Exchange

 Immune Pharmaceuticals Appoints Liquidity Provider to Facilitate Trading on
                        NASDAQ OMX Stockholm Exchange

PR Newswire

TARRYTOWN, N.Y. and HERZLIYA-PITUACH, Israel, Nov. 1, 2013

TARRYTOWN, N.Y. and HERZLIYA-PITUACH, Israel, Nov. 1, 2013 /PRNewswire/
--Immune Pharmaceuticals Inc. (OTCQX and NASDAQ OMX Stockholm Exchange: IMNP)
announced today that it has appointed Erik Penser Bankaktiebolag as a
liquidity provider for the Company's common shares currently listed on NASDAQ
OMX Stockholm Exchange under the trading symbol IMNP. The firm will continue
to be the Company's liquidity provider after its planned transfer of its stock
listing from NASDAQ OMX Stockholm Exchange to NASDAQ OMX First North Premier.

A liquidity provider facilitates the buying and selling of shares in order to
narrow the difference between the bid and ask prices of a traded security.
The liquidity provider's goal is to reduce market risk, enabling shareholders
to more efficiently trade in the Company's common stock. The agreement
between Erik Penser Bankaktiebolag and the Company is consistent with the
terms established by NASDAQ OMX in Stockholm for liquidity providers
pertaining to both the NASDAQ OMX Stockholm Exchange and NASDAQ OMX First
North Premier. The agreement is effective as of November 1, 2013.

About Erik Penser Bankaktiebolag

Erik Penser Bankaktiebolag is a privately owned and independent bank that
offers a broad range of financial services to private and institutional
investors and focuses on creating value for its clients. Erik Penser
Bankaktiebolag has approximately 90 employees and has its office at
Biblioteksgatan 9 in Stockholm, Sweden. Erik Penser Bankaktiebolag operates
under the supervision of the Swedish Financial Supervisory Authority and is a
member of the leading Nordic exchanges, SwedSec and the Swedish Securities
Dealers Association

About Immune Pharmaceuticals Inc.

Immune Pharmaceuticals Inc. (OTCQX and NASDAQ OMX Stockholm Exchange: IMNP)
applies a personalized approach to treatment, developing novel, highly
targeted antibody therapeutics to improve the lives of patients with
inflammatory diseases and cancer. The Company's lead product candidate,
bertilimumab, is entering Phase II clinical studies for moderate to severe
ulcerative colitis and bullous pemphigoid, with additional studies planned for
Crohn's disease and severe asthma. The Company is evaluating the use of its
NanomAb® platform, a second generation antibody drug conjugate technology,
with chemotherapeutics in order to enhance their safety and efficacy profiles
by delivering the medicines directly to cancer cells. The Company's growing
oncology pipeline also includes proprietary antibodies and, clinical-stage
small molecules that have been shown activity in a variety of solid tumors.

Immune is headquartered in Tarrytown, New York, with its primary research and
development facilities in Herzliya-Pituach, Israel.

For more information, visit Immune's website at,
the content of which is not a part of this press release.

Forward-Looking Statements

This news release and any oral statements made with respect to the information
contained in this news release contain forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. You are
urged to consider statements that include the words "may," "will," "would,"
"could," "should," "believes," "estimates," "projects," "potential,"
"expects," "plans," "anticipates," "intends," "continues," "forecast,"
"designed," "goal" or the negative of those words or other comparable words to
be uncertain and forward-looking. Such forward-looking statements include
statements that express plans, anticipation, intent, contingency, goals,
targets, future development and are otherwise not statements of historical
fact. These statements are based on our current expectations and are subject
to risks and uncertainties that could cause actual results or developments to
be materially different from historical results or from any future results
expressed or implied by such forward-looking statements. Factors that may
cause actual results or developments to differ materially include: the risks
associated with the adequacy of our existing cash resources and our ability to
continue as a going concern; the risks associated with our ability to continue
to meet our obligations under our existing debt agreements; the risk that
clinical trials for bertilimumab, crolibulin or AmiKet™ will not be
successful; the risk that bertilimumab, crolibulin, AmiKet™ or compounds
arising from our NanomAb® program will not receive regulatory approval or
achieve significant commercial success; the risk that we will not be able to
find a partner to help conduct the Phase III trials for AmiKet™ on attractive
terms, a timely basis or at all; the risk that our other product candidates
that appeared promising in early research and clinical trials do not
demonstrate safety and/or efficacy in larger-scale or later-stage clinical
trials; the risk that we will not obtain approval to market any of our product
candidates; the risks associated with dependence upon key personnel; the risks
associated with reliance on collaborative partners and others for further
clinical trials, development, manufacturing and commercialization of our
product candidates; the cost, delays and uncertainties associated with our
scientific research, product development, clinical trials and regulatory
approval process; our history of operating losses since our inception; the
highly competitive nature of our business; risks associated with litigation;
and risks associated with our ability to protect our intellectual property.
These factors and other material risks are more fully discussed in our
periodic reports, including our reports on Forms 8-K, 10-Q and 10-K and other
filings with the U.S. Securities and Exchange Commission. You are urged to
carefully review and consider the disclosures found in our filings which are
available at or at You are
cautioned not to place undue reliance on any forward-looking statements, any
of which could turn out to be wrong due to inaccurate assumptions, unknown
risks or uncertainties or other risk factors.

SOURCE Immune Pharmaceuticals Inc.

Contact: Immune Pharmaceuticals Inc.: 777 Old Saw Mill River Road Tarrytown,
NY 10591, Anna Baran, Director of Investor Relations and Corporate
Communications, Tel: (914) 606-3500 or (646) 937-1941;; Immune Pharmaceuticals Ltd.: 15 Aba Even Avenue,
2nd Floor, Herzliya-Pituach, 46733, Israel
Press spacebar to pause and continue. Press esc to stop.